HER2- advanced or metastatic breast cancer: a US payer perspective

Overview of attention for article published in Frontiers in oncology, December 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

twitter: 3 X users

Readers on

mendeley: 4 Mendeley

Summary X

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 18,744 followers.

These findings have implications for Medicaid in determining coverage and reimbursement for ELA in this patient population. Date of Publication: 2023 https://t.co/Qdu6GffpuA #Medicaid

07 Jan 2024

Reply Repost Favourite

RT @FrontOncology: New research: Cost-effectiveness analysis of elacestrant versus standard endocrine therapy for second-/third-line treatm…

20 Dec 2023

Reply Repost Favourite

New research: Cost-effectiveness analysis of elacestrant versus standard endocrine therapy for second-/third-line treatment of patients with HR+/HER2- advanced or metastatic breast cancer: a US payer perspective: Background This study… https://t.co/JEaF93

19 Dec 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.